North America - United States • Healthcare
Proskauer Rose LLP
Proskauer Rose LLP‘s life sciences practice is particularly adept at handling multi-faceted patent disputes concerning biologics, medical devices and pharmaceutical developments, and 2023 saw the team expand with the arrivals of Erik Milch in Washington DC and Joseph Drayton in New York from Cooley LLP in July and October respectively, while Morrison Foerster’s Grant Esposito and David Fioccola also joined the New York office in October. The team is led by Boston’s ‘excellent patent lawyer’ Fangli Chen, whose litigious experience encompasses immunotherapy, gene therapy and editing and vaccines, and managing partner and transactions specialist Daryn Grossman in New York. Siegmund Gutman has left the firm.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
- 'The Proskauer life sciences practice is unique in the close partnership they form with their clients. Project teams are diverse and appropriately staffed both in number and level to provide excellent legal services.'
- 'Special call out for Fangli Chen in her management of the team and her proactive approach.'
- 'The patent team at Proskauer provides insightful, strategic and yet pragmatic advice to its client. Its practice on life sciences is particularly strong, covering both biotech and pharmaceuticals. It is my go-to firm when I need strategic advice to handle complex IP issues.'
- 'Fangli Chen is an excellent patent lawyer with a deep scientific expertise. Her strengths are in the strategic development of complex patent portfolios that really add value to her client.'
Key clients
- Amgen
- SoClean
- Gilead Science, Inc.
- Bayer/Monsanto
- NuVasive, Inc.
- Biocon
- Bachem
- Sanofi Pasteur
- Alvogen
- Takeda Pharmaceutical Company
- Versicolor
- BlueRock Therapeutics
- Church & Dwight
- Akebia
- Translate Bio
- Various Life Sciences
- Beam Therapeutics
Work highlights
- Represented Gilead Sciences, Inc. in a $3.6bn antitrust lawsuit where it was alleged that the pharmaceutical company had engaged in an anticompetitive "pay-for-delay" patent settlement regarding two HIV medications.
- Represented Amgen in a patent case related to a biosimilar akin to Johnson & Johnson's Stelara.
- Advised Translate Bio on their global patent portfolio, encompassing diverse platform technologies and programs, including developing a patent protection strategy for their lipid nanoparticle.
Practice head
The lawyer(s) leading their teams.
Fangli Chen, Daryn Grossman